According to the daily, the deal will enable Aconitum to lift annual exports to 100 million litas (EUR 29 m) within four to five years. Kaunas-based company, which posted sales of 30 million litas in 2011, exported 4.5 million litas worth of production last year. This year's exports are expected to reach 7-8 million litas.
Laimis Akramas, a shareholder of Aconitum and its development director, refused to specify the company the deal had been signed with. He admitted, however, that a contract with one of Europe’s pharmaceutical market leaders had been concluded lately.
“We will sell them Livosil – a liver medicine. Our partners will package it and market with their trademark. Regular large-scale orders will enable us to use existing manufacturing capacity. Moreover, they will pay a license fee for a permission to label our medicines with their trademark,” he said.
Aconitum group includes three companies: Aconitum, which is focused on research, Aurantijus, which deals in the manufacturing and exports of food supplements and drugs, and AkonitPharma, a subsidiary in Belarus, which prepacks products designated for CIS markets.